125 related articles for article (PubMed ID: 7823593)
1. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer.
Wheeler TM; Rogers E; Aihara M; Scardino PT; Thompson TC
J Cell Biochem Suppl; 1994; 19():202-7. PubMed ID: 7823593
[TBL] [Abstract][Full Text] [Related]
2. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
3. Significance of apoptosis in prostatic intraepithelial neoplasia and carcinoma.
Sherwani R; Khan S; Khan N; Kamran M; Husain M
Indian J Pathol Microbiol; 2005 Oct; 48(4):444-7. PubMed ID: 16366091
[TBL] [Abstract][Full Text] [Related]
4. Intermediate biomarkers for chemoprevention of prostate cancer.
van der Kwast TH
IARC Sci Publ; 2001; 154():199-205. PubMed ID: 11220659
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
6. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
7. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
Marshall JR
IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
[TBL] [Abstract][Full Text] [Related]
8. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
9. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
10. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
Pacelli A; Bostwick DG
Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
[TBL] [Abstract][Full Text] [Related]
13. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
14. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia.
Montironi R; Lucarini G; Castaldini C; Galluzzi CM; Biagini G; Fabris G
Anticancer Res; 1996; 16(4A):2057-62. PubMed ID: 8712742
[TBL] [Abstract][Full Text] [Related]
16. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy.
Kronz JD; Shaikh AA; Epstein JI
Hum Pathol; 2001 Apr; 32(4):389-95. PubMed ID: 11331955
[TBL] [Abstract][Full Text] [Related]
17. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma.
Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J
Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840
[TBL] [Abstract][Full Text] [Related]
19. Risk of concurrent prostate cancer in cystoprostatectomy specimens is related to volume of high-grade prostatic intraepithelial neoplasia.
Wiley EL; Davidson P; McIntire DD; Sagalowsky AI
Urology; 1997 May; 49(5):692-6. PubMed ID: 9145972
[TBL] [Abstract][Full Text] [Related]
20. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
